Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280432 | 0.88 | ALDH1A1 (0.49) | ALDH1A1HTTRAB9ATSHRSMN1; SMN2 | |
| SCHEMBL11300231 | 0.75 | ALDH1A1 (0.66) | ALDH1A1HTTRAB9ATSHRSMN1; SMN2 | |
| SCHEMBL6533143 | 0.73 | ALDH1A1 (0.39) | ALDH1A1HTTRAB9ATSHRSMN1; SMN2 | |
| SCHEMBL11693743 | 0.72 | KMT2A (0.49) | ALDH1A1HTTRAB9ATSHRMEN1 | |
| SCHEMBL11164223 | 0.72 | KMT2A (0.57) | ALDH1A1RAB9ATSHRHSD17B10MEN1 | |
| SCHEMBL19349131 | 0.72 | MEN1 (0.61) | ALDH1A1RAB9AHSD17B10MEN1KMT2A | |
| SCHEMBL11673366 | 0.71 | ALDH1A1 (0.56) | ALDH1A1HTTRAB9ATSHRSMN1; SMN2 | |
| SCHEMBL7372724 | 0.70 | ALDH1A1 (0.47) | ALDH1A1HTTRAB9ATSHRSMN1; SMN2 | |
| SCHEMBL7371246 | 0.70 | ALDH1A1 (0.47) | ALDH1A1HTTRAB9ATSHRSMN1; SMN2 | |
| SCHEMBL30131234 | 0.69 | ALDH1A1 (0.62) | ALDH1A1HTTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989634-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| EP-1685102-A4 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| EP-1685102-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047251-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129346-A1 | Melanocortin receptor agonists | MC1R, MC3R, MC5R | ALDH1A1 1226/4885HTT 1199/4885RAB9A 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.